Elevance Health stock trades below fair value as Q2 momentum and analyst support build
Published on 08/28/2026 at 22:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health Inc. (US2855211023) stock is trading in the high $390s on August 28, 2026, with recent quotes showing $396.92 per share on the New York Stock Exchange, down 0.35% from a prior close at $399.11 as intraday trading unfolds. Market data indicate that the shares have slipped $1.41 from the previous close during the current session, underscoring how the stock price has eased even as fundamentals and analyst estimates point to a higher fair value.
Q2 2026 earnings beat and modest revenue growth
Elevance Health last reported quarterly earnings on July 15, 2026, delivering diluted earnings per share of $7.45 for Q2 2026, which exceeded a consensus estimate of $6.21 by $1.24 and highlighted operating strength in its health benefits and services portfolio. Earnings data show that the company generated revenue of $49.83 billion for the quarter, compared with analyst expectations of $48.88 billion, marking a gain of $0.95 billion versus consensus and signaling a top-line beat even in a competitive managed care landscape.
In the same quarter a year earlier, Elevance Health posted earnings per share of $8.84, so the current Q2 2026 EPS figure of $7.45 represents a decline of $1.39 year-over-year, while the business’s revenue was up 0.8% versus the prior-year quarter. This combination of lower EPS but slightly higher revenue suggests that margin dynamics, utilization trends, and investments in growth platforms like Carelon are shaping profitability, a key consideration for investors evaluating whether the current stock level fully reflects future earnings power.
Analyst consensus and valuation gap
Recent coverage of Elevance Health highlights that the company is expected to deliver full-year 2026 earnings per share of 27.18 according to research analyst estimates, pointing to robust ongoing profitability following the Q2 2026 beat. The same overview notes that the stock carries an average price target of $440.90, supported by a consensus rating described as Moderate Buy, implying upside of about $44 from the recent last close around $399.11 and suggesting that analysts see the shares as undervalued relative to their fair value models. Consensus figures also frame expectations for continued EPS delivery, reinforcing the case for a valuation gap at present prices.
A separate valuation-focused overview notes that at a last close of $399.11, widely followed narratives anchor Elevance Health’s fair value at $449.10, indicating a spread of $50 between the market price and intrinsic value assumptions based on revenue, margin, and discount rate inputs. The same analysis explicitly characterizes Elevance Health as underpriced relative to that fair value, with the $449.10 figure emphasizing how the shares could rerate if the company continues to execute on its Q2 2026 momentum and higher outlook. Valuation commentary points to AI-driven efficiency gains and changes in Carelon leadership as framing elements for this narrative, tying operational initiatives directly to the perceived discount in the stock.
Share performance around Q2 2026 report
Sector-level performance tracking of health insurance providers indicates that Elevance Health shares are down 5.1% since the Q2 2026 earnings release and currently trade at $404.91 in that specific peer-comparison snapshot, highlighting a pullback from the post-report levels even though the company delivered an earnings beat and raised its outlook. The Q2 review situates Elevance Health alongside managed care peers, underlining that the stock has lagged despite a supportive earnings trajectory, which may reflect broader sector rotation, regulatory headlines, or profit-taking after prior gains.
At the same time, intraday quote data on August 28, 2026 report a last traded price of $396.92, with the share price having moved from a previous close of $401.17 down to that latest value, encapsulating a daily change of -0.35% within the session. The trading range described between the previous close and the latest print illustrates how Elevance Health stock has eased slightly but remains within a relatively tight band just under $400, a zone that investors watching technical support and resistance levels will be monitoring as they weigh the valuation gap against short-term price action.
Institutional activity and dividend context
Recent filings highlight that institutional investors have been active in Elevance Health shares during 2026, with one disclosure noting that a single institutional account took a position valued at $28.20 million in the company. The filing summary indicates that this investor accumulated shares around the time of the Q2 2026 results, a sign that some long-term holders are using the current valuation gap to build exposure to the health benefits provider.
The same source outlines Elevance Health’s capital return profile, noting a quarterly dividend of $1.72 per share scheduled to be paid on September 25, 2026, to shareholders of record as of September 10, 2026, with an ex-dividend date also on September 10. On an annualized basis, this dividend amounts to $6.88 per share and reflects a yield of 1.7% at the indicated levels, underpinned by a payout ratio of 30.58%. For investors, that combination of a moderate yield, a payout ratio under one-third of earnings, and strong Q2 2026 EPS creates room for continued dividend growth while still funding investment in Carelon and other strategic initiatives that support long-run earnings.
Carelon and AI-enabled efficiency as a product pillar
Within Elevance Health’s diversified operations, the Carelon platform stands out as a representative product and services suite, integrating data, analytics, and care management capabilities in support of health plans, employers, and clinical partners. The valuation-oriented overview on Elevance Health underscores how AI-driven efficiency gains and management changes at Carelon are central to the narrative that positions the stock’s current price around $399.11 against a fair value estimate of $449.10, highlighting Carelon’s role in lifting margins and enhancing service quality. By deploying artificial intelligence to streamline authorizations, optimize network usage, and support clinical decision-making, Carelon aims to reduce medical cost trends while improving outcomes, which in turn feeds back into Elevance Health’s ability to beat earnings expectations as it did in Q2 2026.
Carelon’s business model blends technology, data, and human expertise to deliver integrated solutions that span pharmacy, behavioral health, and complex care coordination, making it a key driver of Elevance Health’s non-insurance revenue streams and a differentiator relative to traditional managed care competitors. The focus on AI-enabled workflows and digital tools is aligned with the company’s broader strategy to modernize its health benefits platform, giving Elevance Health an avenue to capture value from shifting reimbursement models and employer demand for more efficient, outcome-oriented health benefit solutions.
Stock level and investor takeaway
As of the session on August 28, 2026, real-time quotes show Elevance Health stock trading at $396.92 on the New York Stock Exchange, reflecting a modest decline of 0.35% from a previous close at $399.11 within the day and leaving the shares several dollars below the recent peer-comparison snapshot level of $404.91. Intraday data attribute a $1.41 move from the prior close to the latest trade, illustrating how the stock is consolidating just below the $400 mark while analysts’ consensus target of $440.90 and a separate fair value estimate of $449.10 highlight potential upside if the company sustains its Q2 2026 earnings trajectory and margin initiatives.
Read more
Further details on Elevance Health’s recent valuation work and operational initiatives can be found in the underpricing analysis that frames the stock around a fair value of $449.10 following strong Q2 2026 results and a higher outlook. The valuation deep dive provides additional context on revenue assumptions, margin expectations, and discount rates underpinning that fair value estimate, giving investors granular insight into how the current share price compares to long-term cash flow projections.
Fact box
Company: Elevance Health Inc.
ISIN: US2855211023
Ticker: ELV
Exchange: NYSE
Price (as of August 28, 2026, 2:02 p.m. ET): $396.92 USD
Market cap: Data from recent filings and market snapshots describe Elevance Health as a large-cap U.S. health benefits company; specific market capitalization figures fluctuate with the share price and outstanding share count.
Sector / Industry: Health Care / Managed Health Care
Index membership: S&P 500
Next earnings date: Not specified in the available sources
